Deal or Case news
NautaDutilh successfully assisted Pharming Group N.V. with its EUR 125 million convertible bonds issue. The convertible bonds have a term of five years and a coupon of 3.00% per annum and will be listed on the Frankfurt Stock Exchange.

Pharming will use the proceeds, among others, to replace and repay a current loan facility (and thereby significantly reduce its financings costs from 13% to 3%), accelerate expansion of production and commercial capability and to serve as funding for the launch of its recently acquired Leniolisib product.

Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorisation.

NautaDutilh acted as Dutch counsel alongside Covington & Burling LLP. The NautaDutilh team consisted of Petra Zijp, Antonia Netiv, Sabrina Legerstee, Annefleur van Oel, Paul van der Bijl, Koen Biesma and Nina Kielman.

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.